Efficacy of gensenoside-Rg3 combined with synchronous treatment of docetaxel and radiation in elderly patients with non-small cell lung cancer
10.3760/cma.j.issn.0254-9026.2014.09.010
- VernacularTitle:参一胶囊联合多西紫杉醇同步放射治疗老年人非小细胞肺癌疗效观察
- Author:
Xingqiang WANG
;
Mei ZHANG
;
Li LI
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small cell lung;
Saponins;
Radiotherapy
- From:
Chinese Journal of Geriatrics
2014;33(9):961-964
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate efficacy and adverse reactions of gensenoside Rg 3 combined with synchronous docetaxel and radiation treatment in elderly patients with non-small cell lung cancer (NSCLC).Methods 62 elderly patients with NSCLC were randomly divided into 2 groups:treatment group (n=32) were treated with radiotherapy and intravenous infusion of docetaxel and oral gensenoside-Rg3 at the same time,control group (n =30) were treated with radiotherapy and intravenous infusion of docetaxel at the same time.Objective response rate (ORR),disease control rate (DCR),the long term survival and adverse reactions were observed and compared between the two groups.Results The objective response rate and the disease control rate in treatment and control groups were 90.6％ versus 83.3％ and 96.9％ versus 90.0％ respectively,and the differences were not statistically significant (both P＞0.05).Median overall survival (OS) time and 1-,2-and 3-year survival rates in treatment and control groups were 17 months versus 10 months,56.3％ versus 43.3％,49.6％ versus 25.0％,and 27.5％ versus 15.0％,respectively,and the differences were statistically significant (x2 =4.19,P 0.04).The common adverse reactions in the two groups were myelosuppression,gastrointestinal reaction,hair loss,fatigue,joint sore.No one discontinued the treatment due to serious adverse reactions.There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05).Conclusions The gensenoside-Rg3 combined with synchronous treatment with docetaxel and radiation for elderly patients with NSCLC can prolong the survival time,improve quality of life and the prognosis with no significant increase in adverse reactions.
